Continuous Infusion of Ropivacaine Hydrochloride in Reducing Pain After Surgery in Patients With Bladder Cancer

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Bladder Carcinoma, Post-operative Pain

In brief

This randomized phase IV trial studies how well the continuous infusion of ropivacaine hydrochloride works in reducing pain after surgery in patients with bladder cancer. Ropivacaine hydrochloride is an anesthetic drug used to decrease pain by numbing an area of the body without putting the patient to sleep. Continuous infusion of ropivacaine hydrochloride may reduce pain and improve the quality of life for patients after bladder surgery.

Key facts

Study ID

NCT02438852

Run by

University of Southern California

People needed

0

Starts

2019-02-25

Expected to finish

2022-02-25

Last updated by the study team

2019-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Undergoing elective open radical cystectomy
• Ability to understand and the willingness to sign a written informed consent

You may not qualify if…

• Allergy or adverse reaction to ropivacaine (ropivacaine hydrochloride) or any amide type of local anesthesia
• Allergy or adverse reaction to local anesthesia catheter
• Additional surgery at the same time as RC (e.g. nephroureterectomy)
• Coagulopathy
• Thrombocytopenia
• Local or systemic infection
• Pregnancy
• Chronic hepatic disease
• Use of type III antiarrhythmics (e.g. amiodarone)
• History of chronic pain and/or daily opioid use

Where it is running

• USC / Norris Comprehensive Cancer Center — Los Angeles, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.